Study: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
Phase II
· Site: 709 (USA) (Dr. Novak)
· consented 2013-03-03
Adverse events
1
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
serious
reported
2026-08-18
Moderate SYNCOPE — outcome: RECOVERED/RESOLVED; onset 2013-03-07 (study day 5.0); relationship: POSSIBLE; serious criteria: life-threatening
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.